Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

PXS-5505 shows good tolerability and >90% inhibition of target enzymes LOX and LOXL2 in myelofibrosis phase 1c dose escalation study Safety committee approves progression to 6 month phase 2 study SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial...

Related Keywords

Australia ,Taiwan ,United States ,South Korea ,Sydney ,New South Wales ,Russia ,Massachusetts ,Australian ,Gary Phillips ,David Mcgarvey ,Felicity Moffatt ,Gabriela Hobbs ,Linkedin ,Twitter ,Drug Administration ,Pharmaxis Ltd ,Pharmaxis Ltd Disclosure Committee ,Australian Securities Exchange ,Harvard Medical School Clinical ,Australian Leukemia Foundation ,Rudi Michelson Monsoon Communications ,International Working Group ,Myeloproliferative Neoplasms Research ,Assistant Professor ,Harvard Medical School ,Clinical Director ,Massachusetts General Hospital ,Investigational New Drug ,Myelofibrosis Symptom Assessment Form ,Ltd Disclosure ,Chief Financial Officer ,Company Secretary ,Orphan Drug Designation ,Investigational Drug Application ,Duchenne Muscular ,Rudi Michelson ,Monsoon Communications ,